Inovio expands COVID-19 vaccine manufacturing with Kaneka

By The Science Advisory Board staff writers

December 3, 2020 -- Inovio has brought Belgium-based Kaneka Eurogentec on board a global consortium of companies that will be manufacturing its DNA COVID-19 vaccine INO-4800, which is in phase II/III development.

Kaneka Eurogentec, an affiliate of Kaneka Corporation of Tokyo, joins a manufacturing consortium that includes Thermo Fisher Scientific, Richter-Helm BioLogics, and Ology Biosciences. Terms of the deal with Kaneka were not disclosed.

Inovio said that it is planning to produce hundreds of millions of doses of the vaccine worldwide through third-party partners. The investigational vaccine, which is given in two doses, does not require freezing for transport or storage and Inovio said that it is stable at room temperature for up to one year. Development is being funded by the U.S. Department of Defense.

Inovio begins late phase clinical trials for COVID-19 vaccine
Inovio has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the phase II segment of its phase II/III clinical trial...
FDA halts Inovio COVID-19 vaccine trial
The U.S. Food and Drug Administration (FDA) has halted Inovio's clinical trial of its COVID-19 vaccine candidate, INO-4800.
Inovio reports long-term positive results for COVID-19 vaccine
Inovio released results of a nonhuman primate study for its COVID-19 DNA vaccine, INO-4800. The vaccine protected the animals 13 weeks after vaccinations...
Inovio vaccine proves potent against SARS-CoV-2 in preclinical trials
Inovio announced that preclinical data for its INO-4800 vaccine candidate were published in Nature Communications on May 20. The results suggesting...
Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter